PerkinElmer will venture into biomarker discovery and 2D gel alternatives, and possibly add more TOFs to its mass spec lineup as it tries to dig deeper into the proteomics market following the February launch of its MALDI-based prO-TOF, company representatives told ProteoMonitor this week.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.